Chronic liver disease and impaired hepatic glycogen metabolism in argininosuccinate lyase deficiency
Lindsay C Burrage, Simran Madan, Xiaohui Li, Saima Ali, Mahmoud Mohammad, Bridget M Stroup, Ming-Ming Jiang, Racel Cela, Terry Bertin, Zixue Jin, Jian Dai, Danielle Guffey, Milton Finegold, Members of the Urea Cycle Disorders Consortium (UCDC), Sandesh Nagamani, Charles G Minard, Juan Marini, Prakash Masand, Deborah Schady, Benjamin L Shneider, Daniel H Leung, Deeksha Bali, Brendan Lee, Lindsay C Burrage, Simran Madan, Xiaohui Li, Saima Ali, Mahmoud Mohammad, Bridget M Stroup, Ming-Ming Jiang, Racel Cela, Terry Bertin, Zixue Jin, Jian Dai, Danielle Guffey, Milton Finegold, Members of the Urea Cycle Disorders Consortium (UCDC), Sandesh Nagamani, Charles G Minard, Juan Marini, Prakash Masand, Deborah Schady, Benjamin L Shneider, Daniel H Leung, Deeksha Bali, Brendan Lee
Abstract
BACKGROUNDLiver disease in urea cycle disorders (UCDs) ranges from hepatomegaly and chronic hepatocellular injury to cirrhosis and end-stage liver disease. However, the prevalence and underlying mechanisms are unclear.METHODSWe estimated the prevalence of chronic hepatocellular injury in UCDs using data from a multicenter, longitudinal, natural history study. We also used ultrasound with shear wave elastography and FibroTest to evaluate liver stiffness and markers of fibrosis in individuals with argininosuccinate lyase deficiency (ASLD), a disorder with high prevalence of elevated serum alanine aminotransferase (ALT). To understand the human observations, we evaluated the hepatic phenotype of the AslNeo/Neo mouse model of ASLD.RESULTSWe demonstrate a high prevalence of elevated ALT in ASLD (37%). Hyperammonemia and use of nitrogen-scavenging agents, 2 markers of disease severity, were significantly (P < 0.001 and P = 0.001, respectively) associated with elevated ALT in ASLD. In addition, ultrasound with shear wave elastography and FibroTest revealed increased echogenicity and liver stiffness, even in individuals with ASLD and normal aminotransferases. The AslNeo/Neo mice mimic the human disorder with hepatomegaly, elevated aminotransferases, and excessive hepatic glycogen noted before death (3-5 weeks of age). This excessive hepatic glycogen is associated with impaired hepatic glycogenolysis and decreased glycogen phosphorylase and is rescued with helper-dependent adenovirus expressing Asl using a liver-specific (ApoE) promoter.CONCLUSIONOur results link urea cycle dysfunction and impaired hepatic glucose metabolism and identify a mouse model of liver disease in the setting of urea cycle dysfunction.TRIAL REGISTRATIONThis study has been registered at ClinicalTrials.gov (NCT03721367, NCT00237315).FUNDINGFunding was provided by NIH, Burroughs Wellcome Fund, NUCDF, Genzyme/ACMG Foundation, and CPRIT.
Keywords: Amino acid metabolism; Glucose metabolism; Hepatology; Metabolism; Mouse models.
Conflict of interest statement
Conflict of interest: The authors have declared that no conflict of interest exists.
Figures
References
- Shih VE, Littlefield JW, Moser HW. Argininosuccinase deficiency in fibroblasts cultured from patients with argininosuccinic aciduria. Biochem Genet. 1969;3(1):81–83. doi: 10.1007/BF00485974.
- Erez A, et al. Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat Med. 2011;17(12):1619–1626. doi: 10.1038/nm.2544.
- Nagamani SC, et al. Nitric-oxide supplementation for treatment of long-term complications in argininosuccinic aciduria. Am J Hum Genet. 2012;90(5):836–846. doi: 10.1016/j.ajhg.2012.03.018.
- Baruteau J, et al. Expanding the phenotype in argininosuccinic aciduria: need for new therapies. J Inherit Metab Dis. 2017;40(3):357–368. doi: 10.1007/s10545-017-0022-x.
- Brunetti-Pierri N, Erez A, Shchelochkov O, Craigen W, Lee B. Systemic hypertension in two patients with ASL deficiency: a result of nitric oxide deficiency? Mol Genet Metab. 2009;98(1-2):195–197. doi: 10.1016/j.ymgme.2009.06.006.
- Fakler CR, Kaftan HA, Nelin LD. Two cases suggesting a role for the L-arginine nitric oxide pathway in neonatal blood pressure regulation. Acta Paediatr. 1995;84(4):460–462. doi: 10.1111/j.1651-2227.1995.tb13673.x.
- Kho J, et al. Argininosuccinate Lyase Deficiency Causes an Endothelial-Dependent Form of Hypertension. Am J Hum Genet. 2018;103(2):276–287. doi: 10.1016/j.ajhg.2018.07.008.
- Brambilla A, et al. Resting energy expenditure in argininosuccinic aciduria and in other urea cycle disorders. J Inherit Metab Dis. 2019;42(6):1105–1117. doi: 10.1002/jimd.12108.
- Tuchman M, et al. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab. 2008;94(4):397–402. doi: 10.1016/j.ymgme.2008.05.004.
- Mori T, et al. Progressive liver fibrosis in late-onset argininosuccinate lyase deficiency. Pediatr Dev Pathol. 2002;5(6):597–601. doi: 10.1007/s10024-002-0109-7.
- Zimmermann A, Bachmann C, Baumgartner R. Severe liver fibrosis in argininosuccinic aciduria. Arch Pathol Lab Med. 1986;110(2):136–140.
- Marble M, et al. Living related liver transplant in a patient with argininosuccinic aciduria and cirrhosis: metabolic follow-up. J Pediatr Gastroenterol Nutr. 2008;46(4):453–456. doi: 10.1097/MPG.0b013e3180ca8720.
- Parsons HG, Scott RB, Pinto A, Carter RJ, Snyder FF. Argininosuccinic aciduria: long-term treatment with arginine. J Inherit Metab Dis. 1987;10(2)
- Martín-Hernández E, et al. Urea cycle disorders in Spain: an observational, cross-sectional and multicentric study of 104 cases. Orphanet J Rare Dis. 2014;9:187.
- Yaplito-Lee J, Chow CW, Boneh A. Histopathological findings in livers of patients with urea cycle disorders. Mol Genet Metab. 2013;108(3):161–165. doi: 10.1016/j.ymgme.2013.01.006.
- Trevisson E, et al. Argininosuccinate lyase deficiency: mutational spectrum in Italian patients and identification of a novel ASL pseudogene. Hum Mutat. 2007;28(7):694–702. doi: 10.1002/humu.20498.
- Al-Sayed M, et al. Identification of a common novel mutation in Saudi patients with argininosuccinic aciduria. J Inherit Metab Dis. 2005;28(6):877–883. doi: 10.1007/s10545-005-0081-2.
- Kölker S, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. J Inherit Metab Dis. 2015;38(6):1059–1074. doi: 10.1007/s10545-015-9840-x.
- Bigot A, Tchan MC, Thoreau B, Blasco H, Maillot F. Liver involvement in urea cycle disorders: a review of the literature. J Inherit Metab Dis. 2017;40(6):757–769. doi: 10.1007/s10545-017-0088-5.
- Ranucci G, et al. Chronic liver involvement in urea cycle disorders. J Inherit Metab Dis. 2019;42(6):1118–1127. doi: 10.1002/jimd.12144.
- Travers H, Reed JS, Kennedy JA. Ultrastructural study of the liver in argininosuccinase deficiency. Pediatr Pathol. 1986;5(3-4):307–318. doi: 10.3109/15513818609068857.
- Badizadegan K, Perez-Atayde AR. Focal glycogenosis of the liver in disorders of ureagenesis: its occurrence and diagnostic significance. Hepatology. 1997;26(2):365–373. doi: 10.1002/hep.510260217.
- Wilson JM, Shchelochkov OA, Gallagher RC, Batshaw ML. Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency. Mol Genet Metab. 2012;105(2):263–265. doi: 10.1016/j.ymgme.2011.10.016.
- Koo M, Lipshutz GS, Cederbaum SD, Lassman C. Biopsy-proven Hepatocellular Carcinoma in a 53-year-old Woman With Arginase Deficiency. Pediatr Dev Pathol. 2017;20(6):517–521. doi: 10.1177/1093526617697058.
- Tsang JP, et al. Arginase deficiency with new phenotype and a novel mutation: contemporary summary. Pediatr Neurol. 2012;47(4):263–269. doi: 10.1016/j.pediatrneurol.2012.06.012.
- Baruteau J, et al. Argininosuccinic aciduria fosters neuronal nitrosative stress reversed by Asl gene transfer. Nat Commun. 2018;9(1):3505. doi: 10.1038/s41467-018-05972-1.
- Ashley SN, Nordin JML, Buza EL, Greig JA, Wilson JM. Adeno-associated viral gene therapy corrects a mouse model of argininosuccinic aciduria. Mol Genet Metab. 2018;125(3):241–250. doi: 10.1016/j.ymgme.2018.08.013.
- Batshaw ML, Tuchman M, Summar M, Seminara J, Members of the Urea Cycle Disorders Consortium A longitudinal study of urea cycle disorders. Mol Genet Metab. 2014;113(1-2):127–130. doi: 10.1016/j.ymgme.2014.08.001.
- Balmer C, et al. Mutations and polymorphisms in the human argininosuccinate lyase (ASL) gene. Hum Mutat. 2014;35(1):27–35. doi: 10.1002/humu.22469.
- Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. doi: 10.1002/hep.20701.
- Kim IH, Józkowicz A, Piedra PA, Oka K, Chan L. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA. 2001;98(23):13282–13287. doi: 10.1073/pnas.241506298.
- Gallagher RC, Lam C, Wong D, Cederbaum S, Sokol RJ. Significant hepatic involvement in patients with ornithine transcarbamylase deficiency. J Pediatr. 2014;164(4):720–725.e6. doi: 10.1016/j.jpeds.2013.12.024.
- Laemmle A, et al. Frequency and Pathophysiology of Acute Liver Failure in Ornithine Transcarbamylase Deficiency (OTCD) PLoS ONE. 2016;11(4):e0153358. doi: 10.1371/journal.pone.0153358.
- AlTassan R, Bubshait D, Imtiaz F, Rahbeeni Z. A retrospective biochemical, molecular, and neurocognitive review of Saudi patients with argininosuccinic aciduria. Eur J Med Genet. 2018;61(6):307–311. doi: 10.1016/j.ejmg.2018.01.007.
- Yankol Y, Mecit N, Kanmaz T, Acarli K, Kalayoglu M. Argininosuccinic Aciduria-A Rare Indication for Liver Transplant: Report of Two Cases. Exp Clin Transplant. 2017;15(5):581–584.
- Newnham T, et al. Liver transplantation for argininosuccinic aciduria: clinical, biochemical, and metabolic outcome. Liver Transpl. 2008;14(1):41–45. doi: 10.1002/lt.21297.
- Özçay F, Barış Z, Moray G, Haberal N, Torgay A, Haberal M. Report of 3 Patients With Urea Cycle Defects Treated With Related Living-Donor Liver Transplant. Exp Clin Transplant. 2015;13 Suppl 3:126–130.
- Kabbany MN, et al. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Am J Gastroenterol. 2017;112(4):581–587. doi: 10.1038/ajg.2017.5.
- Göğüş S, et al. Histologic features of the liver in type Ia glycogen storage disease: comparative study between different age groups and consecutive biopsies. Pediatr Dev Pathol. 2002;5(3):299–304. doi: 10.1007/s10024-001-0139-6.
- Kishnani PS, et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med. 2014;16(11):e1. doi: 10.1038/gim.2014.128.
- Roscher A, et al. The natural history of glycogen storage disease types VI and IX: Long-term outcome from the largest metabolic center in Canada. Mol Genet Metab. 2014;113(3):171–176. doi: 10.1016/j.ymgme.2014.09.005.
- Tsilianidis LA, et al. Aggressive therapy improves cirrhosis in glycogen storage disease type IX. Mol Genet Metab. 2013;109(2):179–182. doi: 10.1016/j.ymgme.2013.03.009.
- Halaby CA, et al. Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring. Genet Med. 2019;21(12):2686–2694. doi: 10.1038/s41436-019-0561-7.
- Floettmann E, et al. Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases. Toxicol Pathol. 2010;38(3):393–401. doi: 10.1177/0192623310362707.
- Miles L, Heubi JE, Bove KE. Hepatocyte glycogen accumulation in patients undergoing dietary management of urea cycle defects mimics storage disease. J Pediatr Gastroenterol Nutr. 2005;40(4):471–476. doi: 10.1097/01.MPG.0000157200.33486.CE.
- Lee TY, et al. dbSNO: a database of cysteine S-nitrosylation. Bioinformatics. 2012;28(17):2293–2295. doi: 10.1093/bioinformatics/bts436.
- Baruteau J, et al. Argininosuccinic aciduria: Recent pathophysiological insights and therapeutic prospects. J Inherit Metab Dis. 2019;42(6):1147–1161. doi: 10.1002/jimd.12047.
- Nagamani SC, et al. A randomized controlled trial to evaluate the effects of high-dose versus low-dose of arginine therapy on hepatic function tests in argininosuccinic aciduria. Mol Genet Metab. 2012;107(3):315–321. doi: 10.1016/j.ymgme.2012.09.016.
- Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T, MULTIVIRC Group Groupe d’Etude Multidisciplinaire sur les Pathologies Liées au Virus C. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol. 2002;97(9):2419–2425. doi: 10.1111/j.1572-0241.2002.05997.x.
- Barr RG. Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology. 2015;276(3):845–861.
- Lederer B, Van Hoof F, Van den Berghe G, Hers H. Glycogen phosphorylase and its converter enzymes in haemolysates of normal human subjects and of patients with type VI glycogen-storage disease. A study of phosphorylase kinase deficiency. Biochem J. 1975;147(1):23–35. doi: 10.1042/bj1470023.
- Lederer B, Stalmans W. Human liver glycogen phosphorylase. Kinetic properties and assay in biopsy specimens. Biochem J. 1976;159(3):689–695. doi: 10.1042/bj1590689.
- Brown BI, Brown DH. Definitive assays for glycogen debranching enzyme in human fibroblasts. In: Schotland DL, ed. Disorders of the motor unit. New York, New York, USA: J. Wiley; 1982:667–673.
- Tuchman M, Brown BI, Burke BA, Ulstrom RA. Clinical and laboratory observations in a child with hepatic phosphorylase kinase deficiency. Metab Clin Exp. 1986;35(7):627–633. doi: 10.1016/0026-0495(86)90169-1.
- Brown DH, Brown BI. Studies of the residual glycogen branching enzyme activity present in human skin fibroblasts from patients with type IV glycogen storage disease. Biochem Biophys Res Commun. 1983;111(2):636–643. doi: 10.1016/0006-291X(83)90354-6.
- L’herminé-Coulomb A, et al. Fetal type IV glycogen storage disease: clinical, enzymatic, and genetic data of a pure muscular form with variable and early antenatal manifestations in the same family. Am J Med Genet A. 2005;139A(2):118–122. doi: 10.1002/ajmg.a.30945.
Source: PubMed